Radcliffe Capital Management’s Zura Bio ZURA Stock Holding History

Radcliffe Capital Management’s Portfolio ZURA Stock Details ZURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,697	Closed	-$2.56M	–	709
2022 Q4	$2.56M	Hold	250,697	–	–	0.08%	396
2022 Q3	$2.52M	Buy	250,697 +697	+0.3%	+$6.97K	0.06%	537
2022 Q2	$2.49M	Hold	250,000	–	–	0.06%	567
2022 Q1	$2.48M	Hold	250,000	–	–	0.06%	548
2021 Q4	$2.47M	Hold	250,000	–	–	0.06%	463
2021 Q3	$2.46M	Buy	+250,000	New	+$2.45M	0.07%	398

Other funds holding ZURA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Radcliffe Capital Management's ZURA Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Zura Bio (ZURA) in Q1 2023, closing a stake of 250,697 shares — an estimated $2.56M sold.

Radcliffe Capital Management first reported a position in ZURA in Q3 2021 and held it in 6 quarters. The position peaked at $2.56M in Q4 2022. 3 funds tracked by Wall St. Rank hold ZURA as of Q1 2023.

Radcliffe Capital Management reported no remaining Zura Bio position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 250,697 Zura Bio shares in Q1 2023, an estimated $2.56M.
Radcliffe Capital Management first reported a position in Zura Bio in Q3 2021 and held it in 6 quarters.
Radcliffe Capital Management's Zura Bio position peaked at $2.56M in Q4 2022.
3 funds tracked by Wall St. Rank held Zura Bio as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.